Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case–control study

Chang, 2014, Perioperative blindness after debulking surgery for ovarian cancer, Taiwan J Obstet Gynecol, 53, 112, 10.1016/j.tjog.2013.08.002

Knafel, 2015, The prospective external validation of International Ovarian Tumor Analysis (IOTA) simple rules in the hands of level I and II examiners, Ultraschall Med

Abdulrahman, 2014, The Risk of Malignancy Index (RMI) in women with adnexal masses in Wales, Taiwan J Obstet Gynecol, 53, 376, 10.1016/j.tjog.2014.05.002

Vargas, 2013, MRI of ovarian masses, J Magn Reson Imaging, 37, 265, 10.1002/jmri.23721

Kim, 2014, Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings, Taiwan J Obstet Gynecol, 53, 343, 10.1016/j.tjog.2013.10.041

Bast, 2005, New tumor markers: CA125 and beyond, Int J Gynecol Cancer, 15, 274, 10.1111/j.1525-1438.2005.00441.x

Givens, 2009, Diagnosis and management of adnexal masses, Am Fam Physician, 80, 815

Cho, 2012, Dramatic changes of CA 125 levels in a pregnant woman with a degenerated subserosal myoma, Taiwan J Obstet Gynecol, 51, 117, 10.1016/j.tjog.2012.01.025

Paek, 2011, Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer, Eur J Obstet Gynecol Reprod Biol, 158, 338, 10.1016/j.ejogrb.2011.05.021

Hellström, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res, 63, 3695

Hellstrom, 2011, Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma, Expert Opin Med Diagn, 5, 227, 10.1517/17530059.2011.559459

Ferraro, 2013, Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review, J Clin Pathol, 66, 273, 10.1136/jclinpath-2012-201031

Chudecka-Głaz, 2015, ROMA, an algorithm for ovarian cancer, Clin Chim Acta, 440, 143, 10.1016/j.cca.2014.11.015

Moore, 2009, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, Gynecol Oncol, 112, 40, 10.1016/j.ygyno.2008.08.031

Park, 2011, Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases, Clin Biochem, 44, 884, 10.1016/j.clinbiochem.2011.04.011

Andersen, 2010, Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer, Gynecol Oncol, 116, 378, 10.1016/j.ygyno.2009.10.087

Bamias, 2011, Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience, Gynecol Oncol, 123, 37, 10.1016/j.ygyno.2011.06.033

Brosens, 2013, Progesterone and FOXO1 signaling: harnessing cellular senescence for the treatment of ovarian cancer, Cell Cycle, 12, 1660, 10.4161/cc.25070

Oesterreich, 2013, Progestins: pro-senescence therapy for ovarian cancer?, Cell Cycle, 12, 1662, 10.4161/cc.25072

Earle, 2006, Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients, J Natl Cancer Inst, 98, 172, 10.1093/jnci/djj019

Rosen, 2005, Potential markers that complement expression of CA125 in epithelial ovarian cancer, Gynecol Oncol, 99, 267, 10.1016/j.ygyno.2005.06.040

Kondalsamy-Chennakesavan, 2013, Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age, Gynecol Oncol, 129, 467, 10.1016/j.ygyno.2013.03.001

Li, 2012, Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis, BMC Cancer, 12, 258, 10.1186/1471-2407-12-258

Lin, 2013, Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis, Eur J Obstet Gynecol Reprod Biol, 167, 81, 10.1016/j.ejogrb.2012.10.036

Braicu, 2014, Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium, J Ovarian Res, 7, 49

Kappelmayer, 2015, Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders, Clin Chim Acta, 438, 35, 10.1016/j.cca.2014.07.040

Ławicki, 2013, The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors, J Ovarian Res, 6, 45

Anastasi, 2013, The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer, J Ovarian Res, 6, 44